COVID-19 Ibuprofen Fears Hit Advil Sales In GSK’s Q2
Executive Summary
Reports that ibuprofen could worsen COVID-19 in the early months of the pandemic hit sales of GSK's leading Advil brand, contributing to a drop in pro-forma Consumer Healthcare turnover in the second quarter of 2020.
You may also be interested in...
Euro Q2 Earnings Preview: GSK, Sanofi, Bayer And Reckitt
Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt are all hoping for a sales boost in Q2 following a difficult Q1 due to the almost non-existent cough and cold season. This earnings preview highlights what to look out for as these four firms report their second-quarter results over the coming weeks.
Tylenol Leads OTC Acetaminophen Sales Surge After Ibuprofen Scare During Pandemic – IRI
J&J leads sales growth in OTC pain relief and allergy categories in 2020 as its brands benefited from competing products’ problems and COVID-19’s impact of consumer habits. IRI reveals winning brands that kept a focus on maintaining health in 2020.
GSK Rides E-Commerce Wave In Choppy COVID Waters
GSK saw investments in e-commerce paying off in 2020 as the firm was able to meet increased demand for consumer health products during the pandemic while many shoppers remained indoors.